Article Text
Statistics from Altmetric.com
Q In patients with type 2 diabetes and evidence of macrovascular disease, does pioglitazone reduce all cause mortality and macrovascular complications?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Endocrine ★★★★★★☆ Cardiology ★★★★★★☆
METHODS
Design
randomised placebo controlled trial (PROactive study).
Allocation
concealed.*
Blinding
blinded (clinicians, patients, data collectors, and outcome assessors).*
Follow up period
mean 34.5 months.
Setting
321 centres (including communities and hospitals) in 19 European countries.
Patients
5238 patients 35–75 years of age (mean age 62 y, 66% men) who had type 2 diabetes, haemoglobin A1c concentration ⩾6.5%, and ⩾1 of the following criteria: myocardial infarction (MI), stroke, percutaneous coronary intervention or coronary artery bypass surgery ⩾6 months previously, acute coronary syndrome ⩾3 months previously, or objective evidence …
Linked Articles
- Glossary